You have 6 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage I adult diffuse mixed cell lymphoma

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +9 more
  • Cryosurgery
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 9, 2022

Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)

Recruiting
  • Lymphoma
  • Radiation Therapy
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 9, 2022

Adult Solid Tumor, Diffuse Large B Cell Lymphoma, Burkitt Lymphoma Trial in United Kingdom (AZD3965)

Completed
Has Results
  • Adult Solid Tumor
  • +2 more
  • Sutton, London, United Kingdom
  • +6 more
Feb 10, 2022

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +13 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 18, 2022

DLBCL Trial in Cleveland (ME-401, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Feb 2, 2022

Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial

Completed
Has Results
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
  • +7 more
Nov 4, 2022

Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma Trial in Rochester (drug, genetic, other)

Withdrawn
  • Hodgkin Lymphoma
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic
Nov 28, 2022

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,

Recruiting
  • HIV Infection
  • +10 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • La Jolla, California
  • +3 more
Dec 7, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022

Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +6 more
  • 8/12-Day Production of Car-T Cells
  • +2 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

Not yet recruiting
  • Mature B-Cell Non-Hodgkin Lymphoma
  • (no location specified)
Sep 6, 2022

NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)

Not yet recruiting
  • NHL, Relapsed, Adult
  • +3 more
  • KUR-502
  • (no location specified)
Aug 2, 2022

Lymphoma Trial in Worldwide (Glofitamab, Tocilizumab, Doxorubicin)

Recruiting
  • Lymphoma
  • Duarte, California
  • +13 more
Aug 18, 2022

Survival of Adult T-cell Leukemia / Lymphoma and Patients

Recruiting
  • Lymphoproliferation Induced by HTLV-1
  • +2 more
    • Paris, France
      Hôpital Necker Enfants Malades
    Sep 26, 2022

    B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

    Active, not recruiting
    • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
    • +11 more
    • Atlanta, Georgia
    • +1 more
    Apr 18, 2022

    Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

    Active, not recruiting
    • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
    • +18 more
    • Anti-ICOS Monoclonal Antibody MEDI-570
    • +2 more
    • Duarte, California
    • +22 more
    Jan 18, 2023

    Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

    Completed
    • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
    • +7 more
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 6, 2022

    Mantle Cell Lymphoma Trial in United States (R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
    • Basking Ridge, New Jersey
    • +4 more
    Dec 1, 2022

    Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides Trial run by the NCI (Recombinant human Interleukin-15

    Completed
    Has Results
    • Adult T-Cell Lymphoma/Leukemia
    • +2 more
    • Recombinant human Interleukin-15 (rhIL-15)
    • Mogamulizumab
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Dec 9, 2022

    Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,

    Active, not recruiting
    • Adult Diffuse Large Cell Lymphoma
    • +2 more
    • DPX-Survivac
    • +2 more
    • Calgary, Alberta, Canada
    • +5 more
    Nov 9, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

    Recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +20 more
    • Chimeric Antigen Receptor T-Cell Therapy
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 11, 2022

    Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

    Not yet recruiting
    • Pediatric Cancer
    • +11 more
    • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
    • Milwaukee, Wisconsin
      Children's Wisconsin
    Sep 14, 2022